Skip to content
DataLookout
Menu

TNT EsophagusNCT07603375

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 51 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Aug 1, 2029 to Sep 21, 2029
    • Start date changed from estimate of Sep 2026 to Oct 21, 2026
    • Study completion date: Feb 2034 to Mar 21, 2034
  2. Notable Recruitment opened
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 8 of 10 entries
    • Site details revised
  3. Notable Start date: Aug 1, 2026 to Sep 2026
    • Site contact updated
    v3
  4. Notable Eligibility criteria expanded, about 9 wordsv2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with Clinical complete response (cCR)
Timeframe: approximately 36 weeks

Secondary (8)

Number of participants with pathologic complete response (pCR)
Number of participants who complete both chemoradiation and chemotherapy
Number of participants with local control
Number of participants with Disease free survival
Time to distant metastasis
Show 3 moreShow less
Overall survival
Number of participants with Local control
Disease free survival

Arms and interventions

Chemoradiation with consolidative chemotherapyExperimental

Participants will receive a standard course of chemoradiation followed by consolidative chemotherapy (FOLFOX regimen at the treating physician's discretion).

Drugs: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)

Sites

1 site in 1 country

  • Duke University Medical CenterDurham, North Carolina, United States